JP2018519302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519302A5 JP2018519302A5 JP2017567289A JP2017567289A JP2018519302A5 JP 2018519302 A5 JP2018519302 A5 JP 2018519302A5 JP 2017567289 A JP2017567289 A JP 2017567289A JP 2017567289 A JP2017567289 A JP 2017567289A JP 2018519302 A5 JP2018519302 A5 JP 2018519302A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- ring
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 125000001153 fluoro group Chemical group F* 0.000 claims description 34
- 125000005843 halogen group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 201000008827 tuberculosis Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15174936 | 2015-07-02 | ||
| EP15174936.3 | 2015-07-02 | ||
| EP16174718.3 | 2016-06-16 | ||
| EP16174718 | 2016-06-16 | ||
| EP16174713 | 2016-06-16 | ||
| EP16174713.4 | 2016-06-16 | ||
| PCT/EP2016/065503 WO2017001661A1 (en) | 2015-07-02 | 2016-07-01 | Antibacterial compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018519302A JP2018519302A (ja) | 2018-07-19 |
| JP2018519302A5 true JP2018519302A5 (enExample) | 2019-08-08 |
Family
ID=56289523
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2017567655A Active JP7099824B2 (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2021194493A Active JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567655A Active JP7099824B2 (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2021194493A Active JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10364232B2 (enExample) |
| EP (3) | EP3316969B1 (enExample) |
| JP (3) | JP2018519302A (enExample) |
| KR (2) | KR102710552B1 (enExample) |
| CN (3) | CN113980015A (enExample) |
| AU (3) | AU2016287477B2 (enExample) |
| BR (1) | BR112017028318B1 (enExample) |
| CA (2) | CA2986326A1 (enExample) |
| CL (1) | CL2017003404A1 (enExample) |
| CO (1) | CO2017013408A2 (enExample) |
| DK (1) | DK3316969T3 (enExample) |
| EA (2) | EA201890201A1 (enExample) |
| ES (1) | ES2914681T3 (enExample) |
| HK (1) | HK1249468A1 (enExample) |
| HR (1) | HRP20220339T1 (enExample) |
| IL (2) | IL256391B (enExample) |
| LT (1) | LT3316969T (enExample) |
| MA (1) | MA42293A (enExample) |
| MD (1) | MD3316969T2 (enExample) |
| MX (2) | MX2017016789A (enExample) |
| PE (1) | PE20180520A1 (enExample) |
| PH (2) | PH12017502297A1 (enExample) |
| PL (1) | PL3316969T3 (enExample) |
| RS (1) | RS63201B1 (enExample) |
| SI (1) | SI3316969T1 (enExample) |
| SM (1) | SMT202200220T1 (enExample) |
| UA (1) | UA125171C2 (enExample) |
| WO (2) | WO2017001660A1 (enExample) |
| ZA (1) | ZA201708692B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6563017B2 (ja) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| EP3760625B1 (en) | 2015-07-02 | 2024-03-27 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| PL3316969T3 (pl) | 2015-07-02 | 2022-06-20 | Janssen Sciences Ireland Unlimited Company | Związki przeciwbakteryjne |
| KR20180053386A (ko) | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| CA3012560A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| CA3012624A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| SG11201807982UA (en) | 2016-03-16 | 2018-10-30 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| MA47420A (fr) * | 2017-02-06 | 2019-12-11 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
| WO2019037860A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| JP2020537667A (ja) | 2017-10-17 | 2020-12-24 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| RU2680972C1 (ru) * | 2018-02-13 | 2019-03-01 | Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" | Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков |
| US20210009583A1 (en) * | 2018-03-12 | 2021-01-14 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| KR102839500B1 (ko) | 2018-08-22 | 2025-07-28 | 아셰뉴론 에스아 | 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염 |
| CN109503631A (zh) * | 2018-12-29 | 2019-03-22 | 中国医学科学院医药生物技术研究所 | 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用 |
| WO2020243224A1 (en) * | 2019-05-28 | 2020-12-03 | Shionogi & Co., Ltd. | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE |
| KR102076958B1 (ko) | 2019-06-24 | 2020-02-13 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| ES2978573T3 (es) | 2019-09-13 | 2024-09-16 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos |
| KR20220075335A (ko) | 2019-09-30 | 2022-06-08 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균 화합물 |
| KR20220071199A (ko) | 2019-09-30 | 2022-05-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4-퀴놀리논 항균 화합물 |
| CA3162532A1 (en) | 2019-12-27 | 2021-07-01 | Augusto Eugenio Pardal Filipe | Antibacterial quinolines |
| AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN117440958A (zh) * | 2021-03-17 | 2024-01-23 | 爱尔兰詹森科学公司 | 抗菌化合物 |
| MX2023010948A (es) | 2021-03-17 | 2023-11-28 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| MX2024000111A (es) | 2021-06-29 | 2024-01-19 | Tecnimede Sociedade Tecnico Medicinal Sa | Compuestos heterociclicos para el tratamiento de tuberculosis. |
| JP2024540052A (ja) | 2021-10-28 | 2024-10-31 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 細菌感染の治療に使用するためのイミダゾピリジンアミド及び関連化合物 |
| CN114957954B (zh) * | 2022-05-16 | 2024-08-20 | 万华化学集团股份有限公司 | 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用 |
| AU2023292503A1 (en) * | 2022-06-15 | 2024-10-31 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025017047A1 (en) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections |
| WO2025129116A1 (en) * | 2023-12-14 | 2025-06-19 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT792273E (pt) | 1994-11-15 | 2003-06-30 | Upjohn Co | Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas |
| DE69614847T2 (de) | 1995-05-11 | 2002-04-04 | Pharmacia & Upjohn Co., Kalamazoo | Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone |
| MXPA05001052A (es) | 2002-07-25 | 2005-04-08 | Janssen Pharmaceutica Nv | Derivados de quinolina y su uso como inhibidores micobacterianos. |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| TW200901969A (en) * | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| NZ587096A (en) | 2008-03-26 | 2011-11-25 | Global Alliance For Tb Drug Dev | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
| AU2009294850B2 (en) | 2008-09-22 | 2015-07-02 | Oregon Health & Science University | Methods for detecting a Mycobacterium tuberculosis infection |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| CN106866667B (zh) | 2009-11-05 | 2019-11-15 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
| RU2576662C2 (ru) * | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EA201490537A1 (ru) | 2011-09-01 | 2014-07-30 | АйАрЭм ЭлЭлСи | СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit |
| BR112014004560A2 (pt) | 2011-09-01 | 2017-04-04 | Irm Llc | compostos e composições como inibidores de c-kit quinase |
| US9822129B2 (en) * | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CA2879460C (en) * | 2012-07-18 | 2021-10-19 | Garrett MORASKI | 5,5-heteroaromatic anti-infective compounds |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| EP3027615B1 (en) | 2013-08-02 | 2021-07-21 | Institut Pasteur Korea | Anti-infective compounds |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| US10080749B2 (en) | 2014-11-03 | 2018-09-25 | The Regents Of The University Of California | Multi-drug therapies for tuberculosis treatment |
| PL3316969T3 (pl) * | 2015-07-02 | 2022-06-20 | Janssen Sciences Ireland Unlimited Company | Związki przeciwbakteryjne |
| CN109415349A (zh) | 2016-06-16 | 2019-03-01 | 爱尔兰詹森科学公司 | 杂环化合物作为抗细菌剂 |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
-
2016
- 2016-07-01 PL PL16734637T patent/PL3316969T3/pl unknown
- 2016-07-01 US US15/736,375 patent/US10364232B2/en active Active
- 2016-07-01 CA CA2986326A patent/CA2986326A1/en active Pending
- 2016-07-01 WO PCT/EP2016/065499 patent/WO2017001660A1/en not_active Ceased
- 2016-07-01 EA EA201890201A patent/EA201890201A1/ru unknown
- 2016-07-01 HR HRP20220339TT patent/HRP20220339T1/hr unknown
- 2016-07-01 EP EP16734637.8A patent/EP3316969B1/en active Active
- 2016-07-01 MA MA042293A patent/MA42293A/fr unknown
- 2016-07-01 US US15/736,524 patent/US20180155341A1/en not_active Abandoned
- 2016-07-01 AU AU2016287477A patent/AU2016287477B2/en active Active
- 2016-07-01 MX MX2017016789A patent/MX2017016789A/es unknown
- 2016-07-01 EP EP22158386.7A patent/EP4074378A1/en not_active Withdrawn
- 2016-07-01 JP JP2017567289A patent/JP2018519302A/ja active Pending
- 2016-07-01 AU AU2016287478A patent/AU2016287478B2/en not_active Expired - Fee Related
- 2016-07-01 HK HK18109081.1A patent/HK1249468A1/zh unknown
- 2016-07-01 UA UAA201800904A patent/UA125171C2/uk unknown
- 2016-07-01 CA CA2986331A patent/CA2986331A1/en not_active Abandoned
- 2016-07-01 KR KR1020187001923A patent/KR102710552B1/ko active Active
- 2016-07-01 EP EP16733105.7A patent/EP3316968A1/en not_active Ceased
- 2016-07-01 ES ES16734637T patent/ES2914681T3/es active Active
- 2016-07-01 MX MX2017016788A patent/MX386598B/es unknown
- 2016-07-01 CN CN202111173668.2A patent/CN113980015A/zh active Pending
- 2016-07-01 RS RS20220464A patent/RS63201B1/sr unknown
- 2016-07-01 MD MDE20180478T patent/MD3316969T2/ro unknown
- 2016-07-01 CN CN201680038659.3A patent/CN107708809A/zh active Pending
- 2016-07-01 WO PCT/EP2016/065503 patent/WO2017001661A1/en not_active Ceased
- 2016-07-01 JP JP2017567655A patent/JP7099824B2/ja active Active
- 2016-07-01 SM SM20220220T patent/SMT202200220T1/it unknown
- 2016-07-01 SI SI201631501T patent/SI3316969T1/sl unknown
- 2016-07-01 LT LTEPPCT/EP2016/065499T patent/LT3316969T/lt unknown
- 2016-07-01 CN CN201680038644.7A patent/CN108235704B/zh active Active
- 2016-07-01 DK DK16734637.8T patent/DK3316969T3/da active
- 2016-07-01 PE PE2017002738A patent/PE20180520A1/es unknown
- 2016-07-01 EA EA201890204A patent/EA201890204A1/ru unknown
- 2016-07-01 KR KR1020187002072A patent/KR20180022833A/ko not_active Ceased
- 2016-07-01 BR BR112017028318-2A patent/BR112017028318B1/pt active IP Right Grant
-
2017
- 2017-12-13 PH PH12017502297A patent/PH12017502297A1/en unknown
- 2017-12-13 PH PH12017502298A patent/PH12017502298A1/en unknown
- 2017-12-18 IL IL256391A patent/IL256391B/en active IP Right Grant
- 2017-12-18 IL IL256379A patent/IL256379A/en unknown
- 2017-12-20 ZA ZA2017/08692A patent/ZA201708692B/en unknown
- 2017-12-26 CO CONC2017/0013408A patent/CO2017013408A2/es unknown
- 2017-12-27 CL CL2017003404A patent/CL2017003404A1/es unknown
-
2019
- 2019-07-02 US US16/460,334 patent/US20190330189A1/en not_active Abandoned
-
2020
- 2020-04-14 US US16/848,337 patent/US11180472B2/en active Active
-
2021
- 2021-09-17 US US17/477,970 patent/US11866419B2/en active Active
- 2021-11-30 JP JP2021194493A patent/JP7516338B2/ja active Active
-
2022
- 2022-01-20 AU AU2022200385A patent/AU2022200385B2/en active Active
-
2023
- 2023-11-29 US US18/523,171 patent/US20240132470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519302A5 (enExample) | ||
| JP2019518046A5 (enExample) | ||
| JP2018524339A5 (enExample) | ||
| JP2019518050A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| PT76336A (de) | Cephalosporinderivate und verfahren zu ihrer herstellung | |
| JP2018511647A5 (enExample) | ||
| JP2011500539A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| JP2013544812A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| JP2019527724A5 (enExample) | ||
| JP2018529690A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2021501756A5 (enExample) | ||
| ZA202200660B (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| PE20220964A1 (es) | Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas | |
| JP2020111571A5 (enExample) | ||
| CA2382247A1 (en) | Azaindoles having serotonin receptor affinity | |
| JP2021501178A (ja) | 虚血性脳卒中の治療のための芳香族スルホンアミド誘導体 | |
| JP2015522592A5 (enExample) | ||
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE |